David F Jenkins
Overview
Explore the profile of David F Jenkins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
224
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goldberg L, Baskin B, Beierle J, Adla Y, Kelliher J, Yao E, et al.
Genes Brain Behav
. 2025 Jan;
24(1):e70009.
PMID: 39801366
Opioid use disorder is heritable, yet its genetic etiology is largely unknown. C57BL/6J and C57BL/6NJ mouse substrains exhibit phenotypic diversity in the context of limited genetic diversity which together can...
2.
Goldberg L, Baskin B, Adla Y, Beierle J, Kelliher J, Yao E, et al.
bioRxiv
. 2024 May;
PMID: 38798314
Opioid use disorder is heritable, yet its genetic etiology is largely unknown. C57BL/6J and C57BL/6NJ mouse substrains exhibit phenotypic diversity in the context of limited genetic diversity which together can...
3.
Bashi A, Coker E, Bulusu K, Jaaks P, Crafter C, Lightfoot H, et al.
Cancer Discov
. 2024 Mar;
14(5):846-865.
PMID: 38456804
Significance: We present the largest cancer drug combination screen published to date with 7 × 7 concentration response matrices for 109 combinations in more than 750 cell lines, complemented by...
4.
Gopinath P, Twayana K, Ravanan P, Thomas J, Mukherjee A, Jenkins D, et al.
Part Fibre Toxicol
. 2021 Sep;
18(1):35.
PMID: 34496914
Background: Today, cosmetic products are very popular with both men and women to improve their appearance and increase their social acceptability. Results: In this study, nano-sized (30-300 nm) plastic particles...
5.
Johnson W, Odom A, Cintron C, Muthaiah M, Knudsen S, Joseph N, et al.
BMC Infect Dis
. 2021 Jan;
21(1):106.
PMID: 33482742
Background: Gene expression signatures have been used as biomarkers of tuberculosis (TB) risk and outcomes. Platforms are needed to simplify access to these signatures and determine their validity in the...
6.
McQuerry J, Jenkins D, Yost S, Zhang Y, Schmolze D, Johnson W, et al.
BMC Cancer
. 2019 Sep;
19(1):881.
PMID: 31488082
Background: Gene expression profiling of rare cancers has proven challenging due to limited access to patient materials and requirement of intact, non-degraded RNA for next-generation sequencing. We customized a gene...
7.
Zhang Y, Jenkins D, Manimaran S, Johnson W
BMC Bioinformatics
. 2018 Jul;
19(1):262.
PMID: 30001694
Background: Combining genomic data sets from multiple studies is advantageous to increase statistical power in studies where logistical considerations restrict sample size or require the sequential generation of data. However,...
8.
Brady S, McQuerry J, Qiao Y, Piccolo S, Shrestha G, Jenkins D, et al.
Nat Commun
. 2018 Feb;
9(1):572.
PMID: 29402882
The originally published version of this Article contained an error in Figure 4. In panel a, grey boxes surrounding the subclones associated with patients #2 and #4 obscured adjacent portions...
9.
Brady S, McQuerry J, Qiao Y, Piccolo S, Shrestha G, Jenkins D, et al.
Nat Commun
. 2017 Nov;
8(1):1231.
PMID: 29093439
Metastatic breast cancer remains challenging to treat, and most patients ultimately progress on therapy. This acquired drug resistance is largely due to drug-refractory sub-populations (subclones) within heterogeneous tumors. Here, we...
10.
Rahman M, MacNeil S, Jenkins D, Shrestha G, Wyatt S, McQuerry J, et al.
Genome Med
. 2017 Apr;
9(1):40.
PMID: 28446242
Background: The growth factor receptor network (GFRN) plays a significant role in driving key oncogenic processes. However, assessment of global GFRN activity is challenging due to complex crosstalk among GFRN...